Treatments:Cancer
From Proteopedia
(Difference between revisions)
| Line 41: | Line 41: | ||
=====Poly ADP ribose polymerase (PARP) inhibitors====== | =====Poly ADP ribose polymerase (PARP) inhibitors====== | ||
* [[Olaparib]] - brand name [[Lynparza]] | * [[Olaparib]] - brand name [[Lynparza]] | ||
| + | =====[[Cyclin-dependent kinases]] inhibitors===== | ||
| + | * [[Palbociclib]] - brand name [[Ibrance]] | ||
| + | * [[Abemaciclib]] - brand name [[Verzenio]] | ||
</td> | </td> | ||
</tr> | </tr> | ||
</table> | </table> | ||
__NOTOC__ | __NOTOC__ | ||
Revision as of 10:54, 29 October 2023
Anti-CD20 Monoclonal Antibody
Anti-melanoma Monoclonal Antibody
B-Raf Kinase Inhibitor
ChemotherapyDihydrofolate Reductase Inhibitor
Epidermal Growth Factor Receptor Inhibitors
Estrogen Receptor Modulator
mTOR inhibitor
Multiple Receptor Tyrosine kinase (VEGFR, PDGFR, EGFR, KIT, Abl) Inhibitors
Vascular Endothelial Growth Factor Inhibitor
Poly ADP ribose polymerase (PARP) inhibitors=Cyclin-dependent kinases inhibitors
|
Proteopedia Page Contributors and Editors (what is this?)
David Canner, Michal Harel, Alexander Berchansky, Karsten Theis
